Built on our proprietary Retinol Binding Protein 4 (RBP4) IP portfolio, our clinical pipeline includes Tinlarebant (LBS-008) , an oral therapy currently in late-stage clinical trials (including the Phase 3 DRAGON and PHOENIX studies) for Stargardt disease (STGD1) and Geographic Atrophy (GA) in dry AMD. This role serves as the primary owner of all HCP-facing promotional activities and collaborates closely with agency partners, commercial operations, sales, medical affairs, legal, regulatory, market access, and field teams to execute integrated omnichannel campaigns.